ABCL

#2365
AbCellera Biologics Inc. Common Shares
3.83 USD
+1.86%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.80
3.84
Intervallo Annuale
1.94
6.52
Variazione giornaliera
+1.86%
Variazione Mensile
+8.50%
Variazione di 6 mesi
-37.32%
Variazione Annuale
+56.97%
Chiusura Precedente
3.76
Apertura
3.80
Bid
Ask
Minimo
3.80
High
3.84
Volume
141
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 1.16 B
  • Employee 562
  • Founded 2012
  • CEO Carl Hansen
  • Website www.abcellera.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00LLW2MF2
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-6.98
Rapporto prezzo/fatturato
13.6

AbCellera Biologics Inc

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Notizie